Oral Contraceptive Pill and GnRH Antagonist Versus Long Protocol in IVF Patients
NCT ID: NCT01157754
Last Updated: 2015-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
115 participants
INTERVENTIONAL
2009-06-30
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GnRH for Luteal Support in IVF/ICSI/FET Cycles
NCT02357654
Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients
NCT01501448
Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days
NCT01093443
Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles
NCT01037699
Short Versus Long Protocol for IVF and IVF+ICSI
NCT00756028
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OCP+GnRH antagonist
Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
levonorgestrel and ethynilestradiol
long GnRH agonist
daily triptorelin starting day 21st of previous cycle
levonorgestrel and ethynilestradiol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
levonorgestrel and ethynilestradiol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \<30 kg/m2
* regular menstrual cycles
* basal FSH \<10 IU and E2 \<60 pg/ml
Exclusion Criteria
* endometriosis
* previous ovarian surgery
* previous low ovarian response
18 Years
38 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IVI Madrid
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Valenciano de Infertilidad
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAD-GV-05-2009-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.